CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM acquires product package from Bristol-Myers Squibb – significant expansion of our portfolio

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

The transaction involves three global niche products that are in high demand for oncology and infectious therapy, respectively: FUNGIZONE® (amphotericin B) is used to treat seriously ill and immunocompromised patients with progressive, potentially life-threatening, fungal infections. VEPESID® (etoposide) and ETOPOPHOS® (etoposide phosphate) are mainly used to treat tumors and fight leukemia.

By acquiring the global rights to this product package, CHEPLAPHARM has succeeded in expanding its presence in strategically important markets. This refers in particular to the French market.

“With this substantial deal, the partnership and trusting cooperation with Bristol-Myers Squibb have been further strengthened - we are very pleased about that. The product package contributes significantly to the future diversification of our global portfolio and thus once again confirms our successful Buy And Build Strategy", says CEO Sebastian F. Braun.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com


Investor Relations topics

Back to top expand_less